 <h1>Bendamustine Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of bendamustine include:</b> fever, neutropenia, skin rash, and chills. <b>Other side effects include:</b> febrile neutropenia, infection, pneumonia, and pruritus.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bendamustine: intravenous powder for solution, intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bendamustine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking bendamustine:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chest pain</li>
<li>chills</li>
<li>cough or hoarseness</li>
<li>diarrhea</li>
<li>fever</li>
<li>headache</li>
<li>joint pain, stiffness, or swelling</li>
<li>lack or loss of strength</li>
<li>lower back, side, or stomach pain</li>
<li>muscle aches</li>
<li>nausea</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>swelling of the feet or lower legs</li>
<li>swollen glands</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Burning or stinging of the skin</li>
<li>fast heartbeat</li>
<li>hives, itching, or rash</li>
<li>irritation</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>redness of the skin</li>
<li>stiffness or swelling</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, flaking, or peeling of the skin</li>
<li>bluish color</li>
<li>changes in skin color</li>
<li>dizziness</li>
<li>pain, tenderness, or swelling of the foot or leg</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of bendamustine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Decreased weight</li>
</ul><p>
<!-- end intravenous powder for solution, intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bendamustine: intravenous powder for injection, intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased lymphocytes (up to 99%), decreased leukocytes (up to 94%), decreased hemoglobin (up to 89%), decreased neutrophils (up to 86%), decreased platelets (up to 86%), lymphocytopenia (up to 74%), neutropenia (up to 45%), thrombocytopenia (up to 39%), anemia (up to 38%), leukopenia (up to 37%)</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia, hemorrhage, lymphopenia</p>
<p><b>Very rare</b> (less than 0.01%): Hemolysis</p>
<p><b>Postmarketing reports</b>: Pancytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 77%), diarrhea (up to 42%), vomiting (up to 40%), constipation (up to 31%), stomatitis (up to 21%), abdominal pain (up to 14%), dyspepsia (up to 14%), gastroesophageal reflux disease (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Dry mouth, upper abdominal pain, abdominal distension, oral candidiasis</p>
<p><b>Very rare</b> (less than 0.01%): Gastrointestinal hemorrhage, hemorrhagic esophagitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 64%), infectious episodes (up to 37%), pyrexia (up to 36%), chills (up to 14%), asthenia (up to 13%), herpes zoster (up to 12%), mucosal inflammation</p>
<p><b>Common</b> (1% to 10%): Pain, infection, herpes simplex, amenorrhea, epididymitis, thirst, cytomegalovirus infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Sepsis</p>
<p><b>Very rare</b> (less than 0.01%): Infertility, multi-organ failure</p>
<p><b>Frequency not reported</b>: Septic shock, general physical health deterioration<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated bilirubin (up to 34%), increased creatinine, increased urea</p>
<p><b>Common</b> (1% to 10%): Increased AST, increased ALT, increased alkaline phosphatase</p>
<p><b>Frequency not reported</b>: Hepatitis, hepatic failure, gallbladder pain<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (up to 24%), decreased weight (up to 20%), dehydration (up to 15%), decreased appetite (up to 13%), hypokalemia (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Hyperuricemia, tumor lysis syndrome, hypomagnesemia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 22%), dyspnea (up to 17%), upper respiratory tract infection (up to 10%), pharyngolaryngeal pain (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Nasopharyngitis, sinusitis, pneumonia, wheezing, nasal congestion, pulmonary dysfunction</p>
<p><b>Very rare</b> (less than 0.01%): Pulmonary fibrosis</p>
<p><b>Frequency not reported</b>: Lung neoplasm, lung infiltration, pleural effusion</p>
<p><b>Postmarketing reports</b>: Pneumocystis jiroveci pneumonia, pneumonitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 21%), dizziness (up to 15%), dysgeusia (up to 11%)</p>
<p><b>Rare</b> (less than 0.1%): Somnolence, aphonia</p>
<p><b>Very rare</b> (less than 0.01%): Paresthesia, peripheral sensory neuropathy, anticholinergic syndrome, neurological disorders, ataxia, encephalitis</p>
<p><b>Frequency not reported</b>: Paraplegia, neuralgia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 16%), erythema (up to 16%), skin allergic reactions (up to 15%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, dry skin, night sweats, hyperhidrosis, alopecia, skin disorders</p>
<p><b>Rare</b> (less than 0.1%): Dermatitis, macular-papular rash</p>
<p><b>Frequency not reported</b>: Toxic skin reactions, bullous exanthema, urticaria</p>
<p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 15%)</p>
<p><b>Common</b> (1% to 10%): Anxiety, depression<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Tachycardia, chest pain, hypotension, cardiac dysfunction (palpitations, angina pectoris, arrhythmia), hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Pericardial effusion</p>
<p><b>Rare</b> (less than 0.1%): Myocardial infarction, acute circulatory failure, cardiac failure</p>
<p><b>Very rare</b> (less than 0.01%): Phlebitis</p>
<p><b>Frequency not reported</b>: Vasculitis</p>
<p><b>Postmarketing reports</b>: Atrial fibrillation, congestive heart failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Arthralgia, extremity pain, bone pain, myalgia</p>
<p><b>Frequency not reported</b>: Sacral pain<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 11%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reactions</p>
<p><b>Rare</b> (less than 0.1%): Anaphylaxis, anaphylactoid reaction</p>
<p><b>Very rare</b> (less than 0.01%): Anaphylactic shock<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site pain, catheter site pain</p>
<p><b>Frequency not reported</b>: Extravasation injury, infusion reactions, injection site reactions<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Retinal detachment<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Pre-malignant and malignant diseases/secondary tumors<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_2">2. "Product Information. Treanda (bendamustine)." Cephalon Inc, West Chester, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Are lung nodules common after Bendeka &amp; Rituxan therapy?</li>
<li>Why has Bendeka replaced Treanda?</li>
<li>How is Bendeka different to Treanda?</li>
<li>How often is Bendeka given and how long does treatment last?</li>
<li>Does Treanda cause hair loss?</li>
<li>What is Treanda used for and how does it work?</li>
<li>What is Bendeka used for?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about bendamustine</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: alkylating agents</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bendamustine Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Bendeka, Treanda, Belrapzo</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Hodgkin's Lymphoma</li>
<li>Chronic Lymphocytic Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bendamustine: intravenous powder for injection, intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Decreased lymphocytes (up to 99%), decreased leukocytes (up to 94%), decreased hemoglobin (up to 89%), decreased neutrophils (up to 86%), decreased platelets (up to 86%), lymphocytopenia (up to 74%), neutropenia (up to 45%), thrombocytopenia (up to 39%), anemia (up to 38%), leukopenia (up to 37%)</p><p><b>Common</b> (1% to 10%): Febrile neutropenia, hemorrhage, lymphopenia</p><p><b>Very rare</b> (less than 0.01%): Hemolysis</p><p><b>Postmarketing reports</b>: Pancytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 77%), diarrhea (up to 42%), vomiting (up to 40%), constipation (up to 31%), stomatitis (up to 21%), abdominal pain (up to 14%), dyspepsia (up to 14%), gastroesophageal reflux disease (up to 11%)</p><p><b>Common</b> (1% to 10%): Dry mouth, upper abdominal pain, abdominal distension, oral candidiasis</p><p><b>Very rare</b> (less than 0.01%): Gastrointestinal hemorrhage, hemorrhagic esophagitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 64%), infectious episodes (up to 37%), pyrexia (up to 36%), chills (up to 14%), asthenia (up to 13%), herpes zoster (up to 12%), mucosal inflammation</p><p><b>Common</b> (1% to 10%): Pain, infection, herpes simplex, amenorrhea, epididymitis, thirst, cytomegalovirus infection</p><p><b>Uncommon</b> (0.1% to 1%): Sepsis</p><p><b>Very rare</b> (less than 0.01%): Infertility, multi-organ failure</p><p><b>Frequency not reported</b>: Septic shock, general physical health deterioration<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated bilirubin (up to 34%), increased creatinine, increased urea</p><p><b>Common</b> (1% to 10%): Increased AST, increased ALT, increased alkaline phosphatase</p><p><b>Frequency not reported</b>: Hepatitis, hepatic failure, gallbladder pain<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (up to 24%), decreased weight (up to 20%), dehydration (up to 15%), decreased appetite (up to 13%), hypokalemia (up to 11%)</p><p><b>Common</b> (1% to 10%): Hyperuricemia, tumor lysis syndrome, hypomagnesemia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 22%), dyspnea (up to 17%), upper respiratory tract infection (up to 10%), pharyngolaryngeal pain (up to 10%)</p><p><b>Common</b> (1% to 10%): Nasopharyngitis, sinusitis, pneumonia, wheezing, nasal congestion, pulmonary dysfunction</p><p><b>Very rare</b> (less than 0.01%): Pulmonary fibrosis</p><p><b>Frequency not reported</b>: Lung neoplasm, lung infiltration, pleural effusion</p><p><b>Postmarketing reports</b>: Pneumocystis jiroveci pneumonia, pneumonitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 21%), dizziness (up to 15%), dysgeusia (up to 11%)</p><p><b>Rare</b> (less than 0.1%): Somnolence, aphonia</p><p><b>Very rare</b> (less than 0.01%): Paresthesia, peripheral sensory neuropathy, anticholinergic syndrome, neurological disorders, ataxia, encephalitis</p><p><b>Frequency not reported</b>: Paraplegia, neuralgia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 16%), erythema (up to 16%), skin allergic reactions (up to 15%)</p><p><b>Common</b> (1% to 10%): Pruritus, dry skin, night sweats, hyperhidrosis, alopecia, skin disorders</p><p><b>Rare</b> (less than 0.1%): Dermatitis, macular-papular rash</p><p><b>Frequency not reported</b>: Toxic skin reactions, bullous exanthema, urticaria</p><p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 15%)</p><p><b>Common</b> (1% to 10%): Anxiety, depression<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema (up to 14%)</p><p><b>Common</b> (1% to 10%): Tachycardia, chest pain, hypotension, cardiac dysfunction (palpitations, angina pectoris, arrhythmia), hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Pericardial effusion</p><p><b>Rare</b> (less than 0.1%): Myocardial infarction, acute circulatory failure, cardiac failure</p><p><b>Very rare</b> (less than 0.01%): Phlebitis</p><p><b>Frequency not reported</b>: Vasculitis</p><p><b>Postmarketing reports</b>: Atrial fibrillation, congestive heart failure<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (up to 14%)</p><p><b>Common</b> (1% to 10%): Arthralgia, extremity pain, bone pain, myalgia</p><p><b>Frequency not reported</b>: Sacral pain<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 11%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reactions</p><p><b>Rare</b> (less than 0.1%): Anaphylaxis, anaphylactoid reaction</p><p><b>Very rare</b> (less than 0.01%): Anaphylactic shock<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site pain, catheter site pain</p><p><b>Frequency not reported</b>: Extravasation injury, infusion reactions, injection site reactions<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Retinal detachment<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Pre-malignant and malignant diseases/secondary tumors<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Acute renal failure<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Bendeka (bendamustine)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_2">2. "Product Information. Treanda (bendamustine)." Cephalon Inc, West Chester, PA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Are lung nodules common after Bendeka &amp; Rituxan therapy?</li>
<li>Why has Bendeka replaced Treanda?</li>
<li>How is Bendeka different to Treanda?</li>
<li>How often is Bendeka given and how long does treatment last?</li>
<li>Does Treanda cause hair loss?</li>
<li>What is Treanda used for and how does it work?</li>
<li>What is Bendeka used for?</li>
</ul><h2>More about bendamustine</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: alkylating agents</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bendamustine Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Hodgkin's Lymphoma</li>
<li>Chronic Lymphocytic Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>